financetom
Business
financetom
/
Business
/
Pharming to Cut 20% of Non-Commercial, Non-Medical Headcount; Shares Fall
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Pharming to Cut 20% of Non-Commercial, Non-Medical Headcount; Shares Fall
Oct 6, 2025 9:28 AM

12:14 PM EDT, 10/06/2025 (MT Newswires) -- Pharming Group ( PHAR ) said Monday it is implementing a 20% net reduction in its non-commercial and non-medical headcount, primarily at the company's headquarters in the Netherlands, as part of its organizational restructuring.

The restructuring is a part of a previously shared plan to lower general and administrative, or G&A, expenses, the company said.

Pharming ( PHAR ) aims to cut total G&A costs by 15%, or $10 million per year, and expects to take a one-time restructuring charge of about $7 million in Q4 due to the staff reduction, according to the statement.

Shares of the company fell 3.6% in recent trading Monday.

Price: 15.42, Change: -0.58, Percent Change: -3.62

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Five Below Fiscal Q4 Adjusted Earnings Drop, Net Sales Rise
Five Below Fiscal Q4 Adjusted Earnings Drop, Net Sales Rise
Mar 19, 2025
04:22 PM EDT, 03/19/2025 (MT Newswires) -- Five Below ( FIVE ) reported fiscal Q4 adjusted earnings Wednesday of $3.48 per diluted share, down from $3.65 a year earlier. Analysts polled by FactSet expected $3.38. Net sales for the quarter ended Feb. 1 were $1.39 billion, up from $1.34 billion a year earlier. Analysts surveyed by FactSet expected $1.38 billion....
Rhythm Gets Orphan Drug Label for Setmelanotide in Japan
Rhythm Gets Orphan Drug Label for Setmelanotide in Japan
Mar 19, 2025
04:30 PM EDT, 03/19/2025 (MT Newswires) -- Rhythm Pharmaceuticals ( RYTM ) said Wednesday it has received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for setmelanotide as a treatment for acquired hypothalamic obesity. Setmelanotide is currently in a global phase 3 trial, with topline results anticipated in Q2, the biopharmaceutical company said. Acquired hypothalamic obesity is...
BRIEF-EZCORP terminates acquisition agreement with Presta Dinero
BRIEF-EZCORP terminates acquisition agreement with Presta Dinero
Mar 19, 2025
March 19 (Reuters) - EZCORP Inc ( EZPW ): * EZCORP ANNOUNCES TERMINATION OF ACQUISITION AGREEMENT * EZCORP INC ( EZPW ) - TERMINATED ITS DEFINITIVE AGREEMENT WITH PRESTA DINERO, S.A. DE C.V. Source text: Further company coverage: ...
Worthington Steel Fiscal Q3 Adjusted Earnings, Sales Decline
Worthington Steel Fiscal Q3 Adjusted Earnings, Sales Decline
Mar 19, 2025
04:29 PM EDT, 03/19/2025 (MT Newswires) -- Worthington Steel ( WS ) reported fiscal Q3 adjusted earnings late Wednesday of $0.35 per diluted share, down from $0.99 a year earlier. Net sales for the quarter ended Feb. 28 were $687.4 million, down from $805.8 million a year earlier. Two analysts polled by FactSet expected $711.6 million. Shares of Worthington Steel...
Copyright 2023-2026 - www.financetom.com All Rights Reserved